More people who received semaglutide lost at least 5% of their starting body weight compared to those who received a placebo (86% vs 32%)
A cheaper vial with lower net peptide content may actually cost more per usable dose than a more expensive product with higher purity
D.BishtK
Semaglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist, has demonstrated neuroprotective effects in preclinical studies 13 , including reducing -synuclein accumulation, attenuating lipid peroxidation and neuroinflammation, and supporting dopaminergic neuron survival 14,15
For some commercial groups we also have what we call, Ask a Pharmacistits on the digital platform
Ultimately, each person needs to be their own advocate and work in partnership with their providers to decide whether GLP-1 treatment is the appropriate path forward for their eye and overall health.